Rockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaq


The company, which went public in 2021, laid off a chunk of its workforce less than a year ago.

Previous Lifespan could be renamed 'Brown Health' under new agreement with the RI med school
Next Local multifamily exec Mark Fogelman sees market opportunity ahead